These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28322939)

  • 1. Do We Need to Study Metabolism and Distribution in the Eye: Why, When, and Are We There Yet?
    Argikar UA; Dumouchel JL; Kramlinger VM; Cirello AL; Gunduz M; Dunne CE; Sohal B
    J Pharm Sci; 2017 Sep; 106(9):2276-2281. PubMed ID: 28322939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive insight on ocular pharmacokinetics.
    Agrahari V; Mandal A; Agrahari V; Trinh HM; Joseph M; Ray A; Hadji H; Mitra R; Pal D; Mitra AK
    Drug Deliv Transl Res; 2016 Dec; 6(6):735-754. PubMed ID: 27798766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular delivery systems for topical application of anti-infective agents.
    Duxfield L; Sultana R; Wang R; Englebretsen V; Deo S; Rupenthal ID; Al-Kassas R
    Drug Dev Ind Pharm; 2016 Jan; 42(1):1-11. PubMed ID: 26325119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.
    Lanier OL; Manfre MG; Bailey C; Liu Z; Sparks Z; Kulkarni S; Chauhan A
    AAPS PharmSciTech; 2021 Mar; 22(3):107. PubMed ID: 33719019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic model for ocular drug delivery.
    Tojo K
    Chem Pharm Bull (Tokyo); 2004 Nov; 52(11):1290-4. PubMed ID: 15516748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
    Del Amo EM; Urtti A
    Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ophthalmic drug dosage forms: characterisation and research methods.
    Baranowski P; Karolewicz B; Gajda M; Pluta J
    ScientificWorldJournal; 2014; 2014():861904. PubMed ID: 24772038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.
    Destruel PL; Zeng N; Maury M; Mignet N; Boudy V
    Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of Ocular Bioactivation Potential and the Role of Cytochrome P450 2D Enzymes in Rat.
    Dumouchel JL; Argikar UA; Spear J; Brown A; Dunne CE; Kramlinger VM; Cirello AL; Gunduz M
    Drug Metab Lett; 2017; 11(2):102-110. PubMed ID: 28891437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations.
    Shen J; Lu GW; Hughes P
    Pharm Res; 2018 Sep; 35(11):217. PubMed ID: 30255364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Topical Ocular Drug Delivery.
    Yellepeddi VK; Palakurthi S
    J Ocul Pharmacol Ther; 2016 Mar; 32(2):67-82. PubMed ID: 26666398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs.
    Bu HZ; Gukasyan HJ; Goulet L; Lou XJ; Xiang C; Koudriakova T
    Curr Drug Metab; 2007 Feb; 8(2):91-107. PubMed ID: 17305490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters.
    Attar M; Shen J; Ling KH; Tang-Liu D
    Expert Opin Drug Deliv; 2005 Sep; 2(5):891-908. PubMed ID: 16296785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ocular pharmacokinetics: Topical, intravitreal, and systemic drug application].
    Meyer CH; Krohne TU
    Ophthalmologe; 2014 Feb; 111(2):104-6. PubMed ID: 24510172
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model.
    Moosa RM; Choonara YE; du Toit LC; Tomar LK; Tyagi C; Kumar P; Carmichael TR; Pillay V
    Int J Pharm; 2014 May; 466(1-2):296-306. PubMed ID: 24607446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes.
    Argikar UA; Dumouchel JL; Dunne CE; Bushee AJ
    Drug Metab Rev; 2017 Aug; 49(3):372-394. PubMed ID: 28438049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery.
    Jiao J
    Adv Drug Deliv Rev; 2008 Dec; 60(15):1663-73. PubMed ID: 18845195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in ocular drug delivery.
    Chen H
    J Drug Target; 2015; 23(7-8):597-604. PubMed ID: 26453157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.